ArcticZymes Technologies files new patent application within RNA based therapeutics

Tromsø, Norway, 16^th of March 2023 - ArcticZymes Technologies ASA (OSE: AZT) has filed a new patent application within the field of RNA based therapeutics. The patent application covers a new nuclease enzyme composition and method-of-use in the processing and analysis of RNA for therapeutic purposes. RNA therapy is the treatment or prevention of diseases by using modified RNA molecules. 

Developing RNA for therapeutic purposes is challenging and time consuming and requires high-end instrumentation. The new enzyme can ease and improve the analytical processes for therapeutic RNA for both developers and manufacturers.

There is currently no similar enzyme available on the market. ArcticZymes Technologies has initiated client testing of a prototype, gathering performance data and feedback prior to entering product development.

ArcticZymes Technologies ASA, CSO, Darren Ellis said: "We are excited by the new patent application and prototype and how it can help clients accelerate their processes. This again demonstrates the innovation capabilities at ArcticZymes bringing forward patentable enzyme technology that can aid the development of innovative therapies.”  

For more information, please contact:

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

The Company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes Technologies under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.